AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RARE · NASDAQ · Biotechnology

Ultragenyx Pharmaceutical (RARE)

Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.

$15.65

After hours+0.04 (+0.26%)

At close$15.61(+6.55%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	98	127	109	147	139	165	139	166	160	207	136	214
Cost of revenue	11	12	18	21	21	17	29	23	28	29	30	34
Gross profit	87	115	91	126	118	148	111	143	132	178	106	180
	232	237	257	242	250	270	254	251	303	292	275	255
Research & development	157	161	178	162	170	188	166	165	216	203	187	167
Selling, general & administrative	75	77	78	81	80	82	88	87	87	89	88	88
Operating income	−145	−122	−165	−116	−132	−122	−143	−108	−171	−114	−169	−75
	−14	−5	−5	−14	−1	−11	−7	−6	−9	−14	−15	−16
Interest income	6	9	9	7	11	10	7	6	6	7	6	5
Interest expense	18	17	16	16	16	16	14	14	14	19	21	22
Other non-operating income	−4	−12	−11	−2	−14	−4	−8	−8	−5	−5	−6	−6
Income before tax	−159	−127	−170	−131	−133	−133	−150	−114	−180	−128	−184	−91
Income tax expense	1	−4	0	1	0	0	1	1	1	1	1	1
Net income from continuing operations	−160	−123	−171	−132	−134	−133	−151	−115	−180	−129	−185	−92
Net income	−160	−123	−171	−132	−134	−133	−151	−115	−180	−129	−185	−92
EPS, basic	−$2.23	−$1.52	−$2.03	−$1.52	−$1.40	−$1.39	−$1.57	−$1.17	−$1.81	−$1.29	−$1.84	−$0.90
EPS, diluted	−$2.23	−$1.52	−$2.03	−$1.52	−$1.40	−$1.39	−$1.57	−$1.17	−$1.81	−$1.29	−$1.84	−$0.90
Weighted average shares, basic	72	81	84	87	95	96	96	98	100	100	101	102
Weighted average shares, diluted	72	81	84	87	95	96	96	98	100	100	101	102
EBITDA	−134	−101	−146	−106	−109	−109	−126	−91	−157	−100	−155	−61
Depreciation & amortization	7	8	9	9	9	9	9	9	9	9	8	8
EBIT	−141	−110	−154	−115	−118	−118	−135	−100	−165	−109	−163	−69